

# IMIQUIMOD-INDUCED PSORIASIS MODEL

## QPS PHARMACOLOGY MODELS


### Psoriasis

- ▶ Psoriasis is a chronic recurrent inflammatory skin disease with a complex pathogenesis. Imiquimod (IMQ)-induced psoriasis model is used to evaluate the therapeutic effects of a test article.


### Study Details

- ▶ Groups of 5 female BALB/c mice 8-9 weeks old.
- ▶ One day prior to the IMQ application, all animals are anesthetized for fur removal on their backs and ears.
- ▶ For disease induction, from Day 0 until Day 8, animals (under anesthesia) receive 62.5 mg IMQ on the shaved backs and 5 mg on the right outside ear pinna.
- ▶ The normal control group will be treated with 62.5 mg of Vaseline on the shaved back skin and 5 mg of Vaseline on the right outside ear pinna.
- ▶ The test article, vehicle (10 mL/kg, IP), and the reference are administered intra-peritoneally one hour before IMQ application for a total of 9 days.
- ▶ Body weights, the right ear thickness measurements, and psoriasis area severity index (PASI) scoring are performed on all animals on Days 0, 2, 4, 7, and 9.


IMQ-induced Psoriasis model (BALB/c)



IMQ-induced Psoriasis model (BALB/c)



IMQ-induced Psoriasis model (BALB/c)




# A GLOBAL FULL SERVICE CRO ACROSS USA, EU, ASIA, AND AUSTRALIA

## QPS SERVICES

- ▶ Pharmacology
- ▶ Toxicology
- ▶ DMPK
- ▶ Bioanalysis
- ▶ Translational Medicine
- ▶ Phase I Clinics
- ▶ Regulatory & Medical Affairs
- ▶ Cell Therapy & Leukopak
- ▶ Clinical Research Services

## QPS GLOBAL SITES & NETWORK LOCATIONS



★ QPS Owned Sites  
★ QPS Phase I Partner Sites

**NETWORK LOCATIONS** USA / Austria / Australia / Argentina / Belgium / Bosnia / Brazil / Bulgaria / Chile / China / Croatia / Czech Republic / Denmark / France / Finland / Germany / Hungary / India / Italy / Lithuania / Netherlands / Poland / Romania / Serbia / Slovakia / South Africa / South Korea / Spain / Sweden / Taiwan / United Kingdom



Pharmacology



Toxicology



DMPK



Bioanalysis



Translational  
Medicine



Phase I Clinics



Regulatory &  
Medical



Cell Therapy  
& Leukopak

Discover how QPS can accelerate your clinical research.

Email: [infobd@qps.com](mailto:infobd@qps.com) | Phone: 512-350-2827 | Website: [www.qps.com](http://www.qps.com)